Prognostic Value of Increased Integrin-beta 1 Expression in Solid Cancers: a Meta-analysis

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2018 Apr 12

PMID 29636624

Citations 33

Authors

Quanwu Sun

Chuan Zhou

Ruofei Ma

Qianhong Guo

Haiyun Huang

Jie Hao

Hong Liu

Rong Shi

Bo Liu

Affiliations

Soon will be listed here.

Abstract

Integrin-beta 1 (ITGB1) is aberrantly overexpressed or downregulated in solid cancers; however, its prognostic value remains controversial. Therefore, we conducted a meta-analysis to explore whether ITGB1 expression is correlated with overall survival (OS) and the clinicopathological characteristics of patients with solid cancers. We systematically searched the PubMed, Embase, and Web of Science databases for eligible studies published up to June 1, 2017. In total, 22 studies involving 3,666 patients were included. A sensitivity analysis was performed to assess the validity and reliability of the pooled OS. Among the 22 studies, 7 focused on lung cancer, 3 focused on colorectal cancer, 6 focused on breast cancer, 3 involved melanoma, and 3 involved pancreatic cancer. The pooled results showed that high ITGB1 expression was significantly associated with worse OS in lung cancer (pooled hazard ratio [HR]=1.78, 95% CI: 1.19-2.65, <0.05) and breast cancer (pooled HR=1.88, 95% CI: 1.46-2.42, <0.01). In addition, a significant association was observed between high ITGB1 expression and disease-free survival in breast cancer (pooled HR=1.63, 95% CI: 1.17-2.25, <0.001) and pancreatic cancer (pooled HR=2.49, 95% CI: 1.35-4.61, <0.001). However, high ITGB1 expression was not related to OS in colorectal cancer, pancreatic cancer, or melanoma. The pooled HRs used to evaluate the prognostic value of increased ITGB1 expression in lung cancer, breast cancer, and pancreatic cancer were not significantly altered, which indicates that the pooled results were robust. The results of this study indicate that the prognostic value of decreased ITGB1 expression varies among solid cancers.

Citing Articles

Identification of the Interacting Domains Between Tissue Factor and β1-Integrin and the Signalling Properties of the Two Fibronectin-like Domains of Tissue Factor.

Featherby S, Faulkner E, Maraveyas A, Ettelaie C Cancers (Basel). 2025; 17(4).

PMID: 40002240 PMC: 11853675. DOI: 10.3390/cancers17040644.

Clinical relevance of macromolecular complexes involving integrins, potassium and sodium ion channels and the sodium/proton antiporter in human breast cancer.

Lastraioli E, Iorio J, Piazza F, Capitani C, Santillo M, Duranti C Cancer Cell Int. 2025; 25(1):24.

PMID: 39865220 PMC: 11765915. DOI: 10.1186/s12935-025-03653-w.

Integrin β1 in breast cancer: mechanisms of progression and therapy.

Huang Q, Wang J, Ning H, Liu W, Han X Breast Cancer. 2024; 32(1):43-59.

PMID: 39343856 DOI: 10.1007/s12282-024-01635-w.

Does rAj-Tspin, a novel peptide from A. japonicus, exert antihepatocellular carcinoma effects via the ITGB1/ZYX/FAK/AKT signaling pathway?.

Che Y, Lu X, Wang X, Liu Z, Guan L, Li X Cancer Cell Int. 2024; 24(1):290.

PMID: 39143566 PMC: 11325833. DOI: 10.1186/s12935-024-03468-1.

Cancer-associated fibroblast-derived extracellular vesicles promote lymph node metastases in oral cavity squamous cell carcinoma by encapsulating ITGB1 and BMI1.

Lv T, Liu H, Mao L, Song Y, Liao L, Zhong K BMC Cancer. 2024; 24(1):113.

PMID: 38254031 PMC: 10804601. DOI: 10.1186/s12885-024-11855-0.

References

Brooks P, Clark R, Cheresh D . Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science. 1994; 264(5158):569-71. DOI: 10.1126/science.7512751. View

Guo L, Zhang F, Cai Y, Liu T . Expression profiling of integrins in lung cancer cells. Pathol Res Pract. 2009; 205(12):847-53. DOI: 10.1016/j.prp.2009.07.005. View

Guo G, Gong K, Wohlfeld B, Hatanpaa K, Zhao D, Habib A . Ligand-Independent EGFR Signaling. Cancer Res. 2015; 75(17):3436-41. PMC: 4558210. DOI: 10.1158/0008-5472.CAN-15-0989. View

Dos Santos P, Zanetti J, Ribeiro-Silva A, Beltrao E . Beta 1 integrin predicts survival in breast cancer: a clinicopathological and immunohistochemical study. Diagn Pathol. 2012; 7:104. PMC: 3523034. DOI: 10.1186/1746-1596-7-104. View

Hynes R, Zhao Q . The evolution of cell adhesion. J Cell Biol. 2000; 150(2):F89-96. DOI: 10.1083/jcb.150.2.f89. View

Ju L, Zhou C, Li W, Yan L . Integrin beta1 over-expression associates with resistance to tyrosine kinase inhibitor gefitinib in non-small cell lung cancer. J Cell Biochem. 2010; 111(6):1565-74. DOI: 10.1002/jcb.22888. View

Lanzafame S, Emmanuele C, Torrisi A . Correlation of alpha 2 beta 1 integrin expression with histological type and hormonal receptor status in breast carcinomas. Pathol Res Pract. 1996; 192(10):1031-8. DOI: 10.1016/s0344-0338(96)80045-8. View

Huang C, Park C, Hilsenbeck S, Ward R, Rimawi M, Wang Y . β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib. Breast Cancer Res. 2011; 13(4):R84. PMC: 3236347. DOI: 10.1186/bcr2936. View

Chang M, Lee K, Lee K, Kim Y, Kim Y, Kang J . Prognostic role of integrin β1, E-cadherin, and rac1 expression in small cell lung cancer. APMIS. 2011; 120(1):28-38. DOI: 10.1111/j.1600-0463.2011.02788.x. View

10.

Aoudjit F, Vuori K . Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells. Oncogene. 2001; 20(36):4995-5004. DOI: 10.1038/sj.onc.1204554. View

11.

Sawai H, Okada Y, Funahashi H, Matsuo Y, Takahashi H, Takeyama H . Integrin-linked kinase activity is associated with interleukin-1 alpha-induced progressive behavior of pancreatic cancer and poor patient survival. Oncogene. 2006; 25(23):3237-46. DOI: 10.1038/sj.onc.1209356. View

12.

Hu C, Ni Z, Li B, Yong X, Yang X, Zhang J . hTERT promotes the invasion of gastric cancer cells by enhancing FOXO3a ubiquitination and subsequent ITGB1 upregulation. Gut. 2015; 66(1):31-42. DOI: 10.1136/gutjnl-2015-309322. View

13.

Vihinen P, Nikkola J, Vlaykova T, Hahka-Kemppinen M, Talve L, Heino J . Prognostic value of beta1 integrin expression in metastatic melanoma. Melanoma Res. 2000; 10(3):243-51. View

14.

Yao E, Zhang H, Chen Y, Lee B, Chew K, Moore D . Increased beta1 integrin is associated with decreased survival in invasive breast cancer. Cancer Res. 2007; 67(2):659-64. DOI: 10.1158/0008-5472.CAN-06-2768. View

15.

Fujita S, Watanabe M, Kubota T, Teramoto T, Kitajima M . Alteration of expression in integrin beta 1-subunit correlates with invasion and metastasis in colorectal cancer. Cancer Lett. 1995; 91(1):145-9. DOI: 10.1016/0304-3835(95)03735-f. View

16.

Zhou P, Erfani S, Liu Z, Jia C, Chen Y, Xu B . CD151-α3β1 integrin complexes are prognostic markers of glioblastoma and cooperate with EGFR to drive tumor cell motility and invasion. Oncotarget. 2015; 6(30):29675-93. PMC: 4745755. DOI: 10.18632/oncotarget.4896. View

17.

Okamura M, Yamaji S, Nagashima Y, Nishikawa M, Yoshimoto N, Kido Y . Prognostic value of integrin beta1-ILK-pAkt signaling pathway in non-small cell lung cancer. Hum Pathol. 2007; 38(7):1081-1091. DOI: 10.1016/j.humpath.2007.01.003. View

18.

Liu Q, Gao X, Chang W, Gong H, Fu C, Zhang W . Expression of ITGB1 predicts prognosis in colorectal cancer: a large prospective study based on tissue microarray. Int J Clin Exp Pathol. 2016; 8(10):12802-10. PMC: 4680415. View

19.

Scales T, Parsons M . Spatial and temporal regulation of integrin signalling during cell migration. Curr Opin Cell Biol. 2011; 23(5):562-8. DOI: 10.1016/j.ceb.2011.05.008. View

20.

Nikkola J, Vihinen P, Vlaykova T, Hahka-Kemppinen M, Heino J, Pyrhonen S . Integrin chains beta1 and alphav as prognostic factors in human metastatic melanoma. Melanoma Res. 2004; 14(1):29-37. DOI: 10.1097/00008390-200402000-00005. View